Credit Agricole’s Sage Therapeutics SAGE Stock Holding History

Credit Agricole’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-3,224	Closed	-$148K	–	1540
2016 Q3	$148K	Buy	+3,224	New	+$131K	﹤0.01%	1489

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

ORI

Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Credit Agricole's SAGE Position: Q4 2016 in Review

Credit Agricole sold out of Sage Therapeutics (SAGE) in Q4 2016, closing a stake of 3,224 shares — an estimated $148K sold.

Credit Agricole first reported a position in SAGE in Q3 2016 and held it in 1 quarter. The position peaked at $148K in Q3 2016. 165 funds tracked by Wall St. Rank hold SAGE as of Q4 2016.

Credit Agricole reported no remaining Sage Therapeutics position as of Q4 2016 after selling out during the quarter.
Credit Agricole sold 3,224 Sage Therapeutics shares in Q4 2016, an estimated $148K.
Credit Agricole first reported a position in Sage Therapeutics in Q3 2016 and held it in 1 quarter.
Credit Agricole's Sage Therapeutics position peaked at $148K in Q3 2016.
165 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2016.

Based on Credit Agricole's 13F filing for Q4 2016, filed 13 Feb 2017.